Overview and Scope
Zollinger-Ellison syndrome is a rare disorder characterized by gastrin-secreting tumors in the pancreas or duodenum, causing excessive stomach acid production. The treatment of zollinger-ellison syndrome aims to control acid hypersecretion, manage symptoms and address complications related to the condition. The treatment approach may involve medical management, surgical intervention and ongoing monitoring.
Sizing and Forecast
The zollinger-ellison syndrome treatment market size has grown strongly in recent years. It will grow from $1.28 billion in 2023 to $1.35 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to advancements in gastroenterology, increased incidence of zes, multidisciplinary care teams, long-term monitoring.
The zollinger-ellison syndrome treatment market size is expected to see steady growth in the next few years. It will grow to $1.63 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to global healthcare access, genetic screening and diagnosis, personalized treatment plans, regulatory changes and reimbursement policies. Major trends in the forecast period include advanced imaging and diagnostic tools, tailored medications, patient-centered care, minimally invasive interventions.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/zollinger-ellison-syndrome-treatment-global-market-report
Segmentation & Regional Insights
The zollinger-ellison syndrome treatment market covered in this report is segmented –
1) By Diagnosis: Blood Test; CT Scan Ultrasound; X-Ray; Other Diagnosis
2) By Treatment: Chemotherapy; Surgical Resection; Other Treatments
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
4) By End User: Hospitals; Specialty Clinics; Other End Users
Top Major Players:
Pfizer Inc.
- Hoffmann-La Roche Ltd.
- Merck & Co. Inc
- Bayer AG
- Novartis AG
North America was the largest region in the zollinger-ellison syndrome treatment market in 2023.
North America was the largest region in the zollinger-ellison syndrome treatment market in 2023. The regions covered in zollinger-ellison syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13003&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of digestive disorders is expected to propel the growth of the Zollinger-Ellison syndrome treatment market going forward. Digestive disorders are a group of conditions that affect the normal functioning of the digestive system. The digestive system, also called the gastrointestinal (GI) tract, is responsible for breaking down food and absorbing nutrients. Zollinger-Ellison syndrome (ZES) treatment is used to treat digestive disorders such as peptic ulcer disease and gastroesophageal reflux disease (GERD) and the treatment involves reducing the amount of acid produced in the stomach, which can help prevent or treat complications related to peptic ulcers or acid reflux. For instance, in August 2022, according to the National Library of Medicine, a US-based biomedical library and an institute within the National Institutes of Health, peptic ulcer disease (PUD) affects four million people worldwide annually and has an estimated lifetime prevalence of 5-10% in the general population. Additionally, each year, 62 million Americans are diagnosed with all digestive disorders. Therefore, the increasing prevalence of digestive disorders is expected to propel the growth of the Zollinger-Ellison syndrome treatment market.
Key Industry Players
Major players in the zollinger-ellison syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Shionogi & Company Limited, Cipla Limited, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories, Accord Healthcare Limited, Ordain Health Care Global Pvt.Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Biochem Pharmaceuticals Industries Limited.
The zollinger-ellison syndrome treatment market report table of contents includes:
1. Executive Summary
2. Zollinger-Ellison Syndrome Treatment Market Characteristics
3. Zollinger-Ellison Syndrome Treatment Market Trends And Strategies
4. Zollinger-Ellison Syndrome Treatment Market – Macro Economic Scenario
5. Global Zollinger-Ellison Syndrome Treatment Market Size and Growth
…
32. Global Zollinger-Ellison Syndrome Treatment Market Competitive Benchmarking
33. Global Zollinger-Ellison Syndrome Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Zollinger-Ellison Syndrome Treatment Market
35.Zollinger-Ellison Syndrome Treatment Market Future Outlook and Potential Analysis
36. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
